GlassScriptPhysician profile
Jatoria Fair
NPI 1750095634
$2,588.22
in general payments reported to CMS, 2019-2025
25 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,072 · 2024: $1,328 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Travel and Lodging: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.49 |
| Travel and Lodging | $641.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,113.96 | 2023-2025 | Spravato |
| Abbvie INC. | $410.31 | 2023-2024 | |
| Lilly USA, LLC | $202.12 | 2023-2024 | Amyvid, Emgality, Reyvow |
| Eisai INC. | $150.49 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.92 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $73.53 | 2023 | Austedo Xr, Austedo |
| Ucb, INC. | $63.03 | 2023-2024 | Briviact |
| Axsome Therapeutics, INC. | $47.66 | 2024 | Auvelity |
| Corium, LLC | $44.76 | 2023 | Adlarity |
| Lundbeck LLC | $42.16 | 2024 | Vyepti |
| Avion Pharmaceuticals | $39.92 | 2023 | Dhivy |
| Merz Pharmaceuticals, LLC | $37.78 | 2023 | Xeomin |
| Acorda Therapeutics, INC | $35.10 | 2023 | Inbrija, Ampyra |
| Emd Serono, INC. | $29.25 | 2023-2024 | Mavenclad |
| Csl Behring | $26.41 | 2024 | Hizentra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $22.59 | 2023 | Trudhesa |
| Catalyst Pharmaceuticals, INC. | $21.89 | 2023 | Fycompa |
| Nevro Corp. | $21.50 | 2024 | Senza |
| Argenx US, INC. | $20.77 | 2023 | Vyvgart |
| Pfizer INC. | $20.25 | 2023 | |
| Insightec,INC | $19.69 | 2023 | Exablate |
| Amneal Pharmaceuticals LLC | $17.72 | 2023 | Rytary |
| Otsuka America Pharmaceutical, INC. | $15.12 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $14.36 | 2023 | Ongentys |
| Tg Therapeutics, INC. | $13.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jatoria Fair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.